About 4% of patients with NSCLC have a specific chromosomal rearrangement that generates a tumor-specific fusion gene between the EML4 gene (echinoderm microtubule-associated protein-like 4′) and the ALK gene (anaplastic lymphoma kinase). This evidence concerns the gene ALK and neoplasm.